PDS Biotechnology Corporation (PDSB) News
Filter PDSB News Items
PDSB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PDSB News Highlights
- For PDSB, its 30 day story count is now at 6.
- Over the past 21 days, the trend for PDSB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PDSB are PDS, COMP and MET.
Latest PDSB News From Around the Web
Below are the latest news stories about PDS BIOTECHNOLOGY CORP that investors may wish to consider to help them evaluate PDSB as an investment opportunity.
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ETFLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will be hosting a conference call and webcast tomorrow, June 6, 2023, to discuss the promising interim data from the VERSATILE-002 (NCT04260126) Phase 2 clinical trial investigating PDS0101 in combination with Merck’s anti-PD-1 therapy |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time for another dive into the biggest pre-market stock movers as we check out what's happening this morning on Friday! |
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer PatientsInterim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1%A disease control rate (disease stabilization or tumor shrinkage) of 70.6%Median overall survival not yet met Company to host conference call and webcast on June 6, 2023, at 8:00 am ET FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy comp |
PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck CancerCompany plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023FLORHAM PARK, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the immune checkpoint inhibitor naïve group (ICI naïve) of its VERSATILE-002 Phase 2 trial for the treatment of recurrent or metastatic human papi |
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call Transcript May 15, 2023 PDS Biotechnology Corporation misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.31. Operator: Hello, and welcome to the PDS Biotechnology First Quarter 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. As a […] |
Q1 2023 PDS Biotechnology Corp Earnings CallQ1 2023 PDS Biotechnology Corp Earnings Call |
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial ResultsUpdated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended March 31, 2023, and provide a business update on its conference call tod |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial ResultsFLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the first quarter of 2023 on Monday, May 15, 2023, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update. |
PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer PatientsAbstract selected as featured poster to be reviewed by expert panel in the Head and Neck Cancer discussion sessionFLORHAM PARK, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data from the VERSATILE-002 study at the 2023 ASCO® Annual Meeting being held June 2-6 in Chicago. The abstract was |
PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development ProgramFLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease announced the Company received $1.4 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the Company’s participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for |